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Urinary Metabolite Ratios in the Michigan
Cohort Exposed to Polybrominated Biphenyls:
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A field biochemical epidemiology study was conducted using the Michigan cohort consisting of 51 rural
residents exposed to polybrominated biphenyls (PBB). The study had three major objectives: a) to determine
the serum half-life of the major PBB congener, hexabromobiphenyl (HBB), in the human, b) to determine
if the PBB-exposed subjects had elevated cytochrome P4501 function as determined by the caffeine breath
test (CBT) and the caffeine urinary metabolite ratio (CMR), and c) to determine the applicability ofthe CBT
and CMR in field studies. PBB serum levels were detected in 36 ofthe 51 PBB-exposed subjects. The serum
half-life ofHBB was determined by comparing the current serum HBB values to the subject's previous serum
values obtained 5 to 8 years earlier. The median HBB half-life was 12 years (range 4-97 years). The CBT and
CMR were elevated in the subjects exposedtoPBBs ascompared tothe valuesobtainedfrom urbannonsmokers
and were similar to those found in adults who smoke. A gender effect was seen in the PBB-exposed subjects,
the median CBT and CMRvalues ofthe females being lowerthan the values ofmales. There was a correlation
between the CBT and the HBB serum values (r2=0.2, p=0.01) but not between CMR and HBB serum values.
The CBT and CMR were easily conducted in the field and appear to be useful metabolic probes ofcytochrome
P-4501 activity in human environmental toxicology.
Introduction
Contamination ofthe Michigan food chain with polybromi-
nated biphenyls (PBBs) occurred betweenJuly of 1973 and
May of1974 when approximately 295 kg of a mixture ofPBB
congeners, manufactured as a flame retardant (FireMaster
FF-1), was accidentally added to dairy cattle feed (1,2). The
contaminated feed was subsequently shipped to farms and
retail outlets in Michigan, resulting in the dissemination of
the PBBs in the Michigan food chain.
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This PBB exposure hadwidespread effects. Contaminated
cows had a dramatic reduction infeed consumption and milk
production, along with other clinical signs, which eventually
led to the identification of the chemical contamination (3).
Many farms using the contaminated feed were quarantined,
and 30,000 cattle, 2,000 swine, 400 sheep, and 2,000,000
chickens were destroyed andburied. A sample human pop-
ulation study (4) estimated that over 97% of the residents
ofMichigan's lower peninsula had detectable PBB concen-
trations in theiradipose tissues. The humans with the high-
est PBB fat and serumlevels were from families ofquaran-
tined farms who ate their farm products, individuals who
obtained their food directly from these farms, or chemical
workers who manufactured the PBBs (4,5). The Michigan
Department ofPublic Health established a statewide 4,000-
person PBB cohort made up of individuals primarily from
the populations with the highest PBB exposure (5).
The impact of the PBB exposure on human health is a
major concern due to PBB's long half-life in animals and
presumed long half-life in humans and PBB's known biologic
and toxic effects in animals including cancer (6,7), birth
defects (8), hepatic damage (9), and altered immune (10) and
reproductive (11) function. The exposed human populationLAMBERT ET AL.
has been examined for potential PBB-induced toxicities by
many different investigators, as recently reviewed (1,2).
Although some studies have suggested impaired liver, im-
mune, or neurological function, these effects have not been
corroborated, and a conclusive correlation between the PBB
exposure and biologic effect has yet to be demonstrated.
Ifa PBB-induced effect is to be found in the human, the
liver may be the most sensitive organ to monitor. The liver,
in animal studies, has been shown to be an important and
sensitive sentinel organ to monitor PBB-induced biologic
and toxic effects. The liver is the organ where PBBs are
preferentially stored, is effected by PBBs atthe lowest body
burden, and is altered more by PBBs than any other organ
showing dramatic histologic and functional changes
(1,2,9,12-14).
Despite the liver being a sensitive sentinel organ ofPBB
exposure and toxicity in animals, hepatic function in PBB-
exposed humans has been studiedby only afewinvestigators
using relatively insensitive biomarkers ofliver function. In
one study, liver serum enzymes were monitored inMichigan
farmers exposed to PBBs and in Wisconsin farmers not
exposed to PBBs. The Michigan population had a higher
incidence ofabnormnal serumliver enzymes than the Wiscon-
sin subjects (15). However, in a second study, serum liver
enzyme values were within normal range in farmers and
chemical workers exposed to PBBs, butenlared livers were
identified by physical examination in some subjects (16).
These serum liver enzymes have been shown in animals
to be insensitive indicators of polyhalogenated biphenyl-
induced altered hepatic function (1,2).
The hepatic parameter in animals that appears to be the
most sensitive biomarker of polyhalogenated biphenyl-
induced biologic effect, including toxicity, is the cytochrome
P-450-dependent mixed function monooxygenase (P-450)
system (2,12-14). The mammalian P-450 system is a super
gene family ofat least eight enzyme families that are found
in all tissues and is responsible for the metabolism ofmost
environmental chemicals and the synthesis and metabolism
of many endobiotics.
Of the eight P-450 families, family I and/or family II
enzymes are induced by specific PBB congeners. Ofthese
two P-450 families, the P4501 enzyme family in animals
is the most sensitive and important biomarker to monitor
PBB-induced effect (1,2). In fact, the P-450I enzyme(s)
activityis altered atthe lowest dose ofPBB before anyother
hepatic or nonhepatic biomarker is affected (1,2,12-14).
Equally important for its role as apotentialbiomarker, P-450I
activity induction by many polyhalogenated biphenyls can
be predictive ofits potential to be toxic and some species'
orindividual's susceptibility to select chemical-induced toxic
effects. For example, the most toxic congeners ofpolyhalo-
genatedbiphenyls are generallyalso the mostpotentinducers
of the P-450I isozyme(s) activity (1,2,17). Conversely, the
induction ofP450I function in certain strains ofanimals by
select polyhalogenated biphenyls is an indicator of the ani-
mal's genetically controlled susceptibility to develop
chemical-induced toxicities (1,2,17).
In the human, P450I activity may also be a good sen-
tinelbiomarker ofpolyhalogenatedbiphenyl effect. Several
investigators have shown that polychlorinated biphenyls and
polychlorinated dibenzofurans can induce placental P450I
function and the degree of induction correlated with a de-
crease in birth weight (). However, no study has examined
hepatic in vivo P450I activity of humans exposed to any
polyhalogenated biphenyl including PBBs, even though the
value of such human studies has been identified for many
years (2,19).
In this pilot study, caffeine was used as a metabolic probe
ofP450I activity. P450I-dependent caffeine 3-N-demethyl-
ase activity was monitoredbythe caffeine breath test (CBT)
(20), and 7-N-demethylase activity was monitored by the
caffeine urinary metabolite ratio (CMR) (21).
The objectives ofthe study were as follows: a) to identify
the estimated serum half-life of the major PBB congener,
hexabromobiphenyl (HBB), in humans; b) to determine if
the P-450I activity in Michigan rural residents exposed to
PBBs is increased as compared to subjects not exposed to
PBBs; and c) to assess the capacity ofthe CBT and CMR
to serve as metabolic probes in field epidemiology studies.
Methods
Michigan Volunteer Population
Volunteers were selected fromthe4000-subject Michigan
PBB cohort (5). All subjects were healthy; taking no pre-
scribed medications for the previous 2 months or over-the-
counter medications during the 2 days prior to the clinic
visits; nonsmokers for at least the previous 2 years; at least
20 years old; caucasians of primarily Northern European
extraction; and rural residents.
Subjects were selected from the PBB cohort using the
subject's initial enrollment serum PBB, polychlorinated
biphenyl (PCB), and DDT levels determined 5 to 8 years
prior to the present study. An effort was made to select
subjects whose PCB and 1,1-bis(4-chlorophenol)-2,2,2-
trichloroethane (DDT) serum levels were nondetectable or
very low. In order to obtain subjects with a wide range of
PBB body burdens, invitations to participate in the study
were extended to 50 subjects with previously high PBB
serum levels and 50 with nondetectable orlow serumlevels.
There were to be essentially equal number of males and
females. This volunteer population was to be compared to
a previously studied control population ofhealthy caucasian
adult smokers and nonsmokers not exposed to PBBs from
Chicago and Toronto.
Clinical Protocols
Potential adult volunteers received an introductory letter
that briefly outlined the purpose, procedures, and risks of
the study. All selected subjects were subsequently visited
by a field epidemiologist who discussed the study and ob-
tained a verbal commitment to partake in the study. One
week prior to the study day, a letter was sent to the sub-
jects to remind them of the appointment day and protocol
requirements. Volunteers were asked to refrain from in-
gestingproducts which contained methylxanthines such as
chocolate or caffeine for 24 hr prior to the clinic visit and
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not to eat or drink anything except wateraftermidnight prior
to the clinic visits, which were scheduled between 7:30 and
10 A.M.
Volunteers whose medical history metthe protocol criteria
and whose physical examination and urinalysis on the mor-
ning of the study were normal were entered into the caf-
feine study aftersigningthe consent form. A30-cc specimen
of venous blood was drawn from all Michigan subjects for
determination of serum PBB, PCB, and DDT concentra-
tions, and the caffeine breath test was performed.
After the 2-hr CBT, the subjects were offered orangejuice
and rolls before leaving the clinic. The adult volunteers who
were to conductthe CMR were toldthey could resume their
normal diet, but to refrain from ingesting products contain-
ing caffeine or chocolate until final urine samples were col-
lected 10 hr later.
Caffeine Breath Thst
The caffeine substrate used to monitor caffeine 3-N-
demethylation in the CBT was [3-13C-methyl] caffeine
(99% 3C) synthesized by Cambridge Isotopes (Cambridge,
MA) or by A. N. Kotake (20). The labeled caffeine dose,
3 mg/kg (up to a maximal dose of250 mg), was dissolved
in 20 mL of sterile water and ingested by the volunteers,
followed byingestion ofa20-mL waterwashofthe container.
All subjects sat quietly for 15 min before and throughout
the CBT. A breath sample was obtained by having the sub-
ject blow into a plastic bagjust prior to and after the inges-
tion ofthe labeled caffeine at30, 60, 90, and 120 min. Twenty
milliliters of the expired air was removed from the bag by
a syringe and injected into a nonsterile, plain, nonsilicone-
coatedVenoject tube (Terumo Medical Corporation, Elkton,
MD) for transport and storage. The u3CO2/2CO2 ratio was
determined by differential gas-isotope ratio mass spec-
trometry (12,23).
The labeled CO2 exhaled was calculated as percent
labeled dose exhaled per hour (22). The excess '3CO2-
exhaled/mmole '2CO2 for the dose was determined and
multiplied by the calculated CO2 production rate (22,23).
The 2-hr accumulative exhalation of labeled CO2 was the
CBT parameter calculated, since it is the best monitor of
caffeine clearance in the adult (20). The CBT data from the
Michigan PBB cohort was compared to the CBT data from
our control groups of healthy urban Ilinois adult smokers
or nonsmokers without a history ofPBB exposure (20,24).
Caffeine Urinary Metabolite Ratio
All subjects voided prior to ingesting the labeled caffeine.
Just before the subjects left the clinic, they voided again,
and their urine was stored on dry ice. The volunteers were
given a 1-L plastic bottle containing 5 gascorbic acid in which
to collect their urine for an additional 10 hr. Most of the
subjects were instructed to store the urine bottles in the
refrigerator until it was picked up by staff, usually the next
morning. The bottles were thenplaced on dryice for trans-
port to the laboratory. The total volume of the urine was
recorded, and an aliquot was stored at -20°C until analysis.
The urinary metabolites were determined by HPLC, and
7-N-demethylase activity was monitored by determining the
molar ratio of 5-acetylamino-6-formylamino-3-methyluracil
and 1-methyixanthine and 1-uric acid to 1,7-dimethyl uric acid
(21). The CMR data from the PBB cohort were compared
to CMRvalues fromcontrolgroups ofhealthy, white Toronto
adult smokers or nonsmokers who did not have a history
of PBB exposure (21).
Serum PBB, PCB, and DDT Levels
Blood samples from each subject were immediately centri-
fuged and the serum was removed and stored at -20°C.
The PBB, PCB, and DDT serumconcentrations were deter-
mined by gas chromatography and electron capture detec-
tion (25) by the Michigan Department of Public Health's
Analysis Laboratory (EPA quality assurance approved
laboratory forPCB, PBB, and DDT serumvalues, < 9.5%
variation on control sample determinations). Current and
previous values ofPBBs in the Michigan cohort were based
on HBB levels, the dominant PBB congener in FireMaster
FF-1. Other congeners of PBBs were not found in high
enough serum concentrations to be detected. PCB was
quantitated on the basis of Aroclor 1260 standards. The
detection limits were 1 ppb for PBB and DDT and 3 ppb
for PCBs.
The HBB half-life was calculatedby determining the elim-
ination rate ofHBB between the previous and current HBB
serum level and the time required to reduce the previous
sample to one-half the original value. The median HBB
serum half-life for the group was calculated by using only
the data from subjects with current serum HBB values
greater than 5 pbb (slightly above the minimal detection
capacity of the methods) and whose previous value was
greater than the current value.
Statistical Methods
Data for the Michiganvolunteers with and without detec-
table serum levels and the nonexposed urban populations
were compared by the Wilcoxon rank testusing ranked data
in the General Linear Modeling (GLM) procedures ofSAS
(SAS Institute, Cary, NC). Correlationbetween serumPBB
levels and all other variables including the CMR and the
CBT were determined with GLM.
Results
Volunteer Population
One hundred adults from the PBB cohort who met the
clinical protocol criteria were contacted. Seventy-one adult
subjects initially agreed to participate, ofwhich 66 individuals
came to one of the 13 clinics held in Michigan during the
summerof1985. Ofthe 66 subjects who attendedthe clinic,
15 did not meet criteria due to medications taken during
the previous 2 months (12 subjects), abnormalphysical fin-
dings discovered at the time ofthe clinic visit (one subject
with a cardiac arrhythmia, and another with cholecystitis),
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or a history of intolerance to coffee (1 subject). The sub-
jects with abnormal physical findings were referred im-
mediately to their private physicians.
All of the 51 participants resided in rural Michigan, and
the primary occupations ofthe study group was farming or
homemaking on farms. All but one of the farmers were
primarily dairy farmers, and many of the farmers also had
grown cash crops. Most ofthe individuals had lived on PBB-
quarantined farms or directly obtained some of their meat
and milk from these farms. The participants ranged between
20 and 79 years of age, and 25 were females and 26 were
males.
Serum Residue Levels
The HBB serumvalues ofthe Michigan subjects exposed
to PBBs ranged from nondetectable to 860 ppb, with a
median serum concentration of 12 ppb. Fifteen volunteers
did not have detectable PBB serum levels. No correlation
between serum PBB and subject age, weight, or serum PCB
and DDT levels were detected. There was no difference
in serum PBB, PCB, or DDT levels between males and
females.
Serum HBB half-life was determined for the 15 females
and 12 males whose PBB serum values met the criteria
as previously discussed (Fig. 1). The median serum half-
life was 12 years, with a range between 4.6 and 94.7 years.
The serum half-life for females and males was similar.
Three volunteers had current HBB serum values higher
than theirprevious serum values. Ofthese three volunteers,
only one had lost anyweight since theirprevious PBB serum
determination, and that was less than 3% ofthe total body
weight.
Serum PCB levels ranged between undetectable and 99
ppb, with 4 individuals having a serum value greater than
10 ppb and 32 subjects having nondetectable PCB serum
levels. The serum total DDT levels in the subjects ranged
between nondetectable and22.4 ppb. The serum DDTlevels
were greater than 10 ppb in 7 subjects and nondetectable
in 5 subjects.
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FIGURE 1. The alteration of the serum PBB (hexabromobiphenyl) levels with
time. Time 0 represents the current PBB serum levels and the minus
numbers on the abscissa represent the number of years prior to the cur-
rent study that the previous serum samples were obtained. The datafrom
the subjects with serum levels less than 300 ppb (A) and greater than 300
ppb (B).
Caffeine Breath ¶ist
The CBT values for the 51 PBB-exposed Michigan sub-
jects (with and without detectable PBB serum levels) and
our previously reported adult urban control groups of 28
healthy Illinois nonsmokers and 16 smokers (20,24), all of
whomhad not been exposed to PBBs, are shown inFigure
2. The PBB-exposed subjects had higher CBT values as
compared to the urbannonsmokers (p = 0.02), buthad CBT
values not different from the urban smokers.
A comparison between the CBT values and the corre-
sponding PBB serum values of the PBB-exposed subjects
separated according to gender is shown in Figure 3. The
subjects with and without detectable PBB serumlevels had
similar CBT values (median CBT value 5.0% and 5.3% for
the 2-hr accumulative exhaled dose, respectively). There
was a correlation between the serum PBB levels and the
CBT values (r2 = 0.2, p = 0.01). In the PBB-exposed sub-
jects, the CBT values were greater in the males than the
females (median CBT values 6.6% and 4.3% dose exhaled
per 2 hr, respectively, p = 0.05).
Caffeine Urinary Metabolites
The CMRs were determined in only 44 of the PBB-
exposed subjects because 7 subjects did not complete the
urine collection or ingested caffeine prior to the end ofthe
urine collection. The CMR values ofthe Michigan subjects,
as compared to the CMR values from 27 unexposed adult
smokers and 40 nonsmokers from Toronto [previously
reported (21)], is shown in Figure 4. The CMR values in
the PBB-exposed subjects were higher than those of the
urban nonsmokers who were not exposed to PBBs
(P<0.05). In the PBB-exposed subjects, the CMR values
were higher in the males than the females (median CMR
values were 7.5 and 54, respectively, p = 0.01). There was
no correlation between CMR values and PBB levels. The
correlation between the CBT and CMR in the 44 subjects
who completed both tests was significant (r2 = 0.54, p <
0.001).
Discussion
Thirty-six ofthe 51 PBB-exposed subjects had detectable
PBB serum levels, and these serum levels were very high
(4). The current median serum HBB level was 12 ppb,
whereas less than 8% of the general Michigan population
had serum levels above 3.1 ppb in 1978. Although 15 ofthe
subjects did not have detectable levels, we assumed these
subjects had PBB bodyburdens because 97% ofallresidents
of lower Michigan in 1978 had detectable PBB concentra-
tions in adipose tissue (4), and the subjects in the present
study were fromthe Michigan cohort withthe history ofthe
largest PBB exposure. Fatbiopsies would have been much
more sensitive in assessing the PBB body burdens, as the
adipose tissue contains approximately 300 times the con-
centration found in the serum (4), but the biopsies were
not performed since most ofthe subjects would have refused
to volunteer for such a study.
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FIGURE 2. The distribution of the caffeine breath test values in the Michigan
rural adults exposed to PBBs and the Illinois urban adult smokers and non-
smokers without PBB exposure. The horizontal line through each group's
data points represents the median value of that group.
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FIGURE 3. The correlation between the CBT and the PBB (hexabromobi-
phenyl) serum levels in the subjects exposed to PBB. (0) females; (])
males. The PBB-exposed subjects without detectable PBB serum levels
are also represented on the left side of the graph (nondet). The regres-
sion line was calculated by using only the data from the subjects with detec-
table PBB serum levels (CBT = 4.96 + 0.0464 x PBB; r2 = 0.2, p =
0.01).
The current and previous PBB serum determination were
performed by the Michigan Department of Public Health
Laboratory using essentially the same standard method (25).
The gas chromatography assay monitors all PBB congeners,
but the congener routinely monitored and reported was the
HBB (25), since itis the major congener in FireMaster FF-1
and the only measurable PBB congenerin most ofthe serum
samples.
The calculated median HBB half-life was 12 years. The
serum half-life can only be considered an estimate because
serum PBB levels in an individual can fluctuate from week
to week due to factors yet identified (Humphrey, unpublished
data); the time between the two serum determinations was
only 5 to 8 years, and half-life estimates are most accurate
when based on observing the serum levels over at least
FIGURE 4. The distribution of the caffeine metabolic ratios values of the
Michigan subjects exposed to PBBs and the Toronto smokers and non-
smokers not exposed to PBBs. The median value of each group is
represented by the horizontal line.
1.5 half-life (18 years in this case), and there may be contin-
ued PBB exposure of some ofthe subjects since three sub-
jects (without significant weight loss) had slightly increased
current serum PBB levels as compared to their previous
serum levels. Despite all the potential confounders, the
observed 12-year median half-life calculated in this study
is the only data available from humans studied over so many
years. The previous estimate for PBB half-life was 6.7 years
(26), and this was based on data derived from rodent studies.
The subjects used for comparison to the rural Michigan
PBB-exposed subjects were urban Chicago and Toronto
caucasian smokers and nonsmokers whose data have been
previously reported (20,21,24). The PBB, PCB, or DDT
serum levels of the urban residents were not determined
at the time they were studied. However, the subjects should
not have had any PBB or abnormally high PCB body burdens
since the PBB contamination did not extend to Ontario or
IDlinois; nor had the subjects eaten unusual quantities ofLake
Michigan fish, the primary source of high PCB exposure
in the Great Lakes area. All subjects of each group were
caucasian but were not matched for age orgender; however,
we and others have not found gender- or age-related changes
in the CMR or the CBT (20,21,28). The groups were not
studied simultaneously, but the serum determinations and
methodology were well controlled and standardized (as dis-
cussed earlier), and the CBT has been shown not to vary
over 10% in the same subjects repeatedly studied during
an 18-month period (28).
A central objective ofthe study was to monitor the P450I
activity in PBB-exposed subjects and to determine ifPBBs
induce the isozyme(s) in the human. The CBT and CMR
were developed to indirectly determine P-450I isozyme(s)
activity by monitoring caffeine N-demethylation. A number
ofprevious studies have shown the CBT and CMR monitors
P-450I activities. In the rodent, caffeine clearance and the
CBT are induced by polyaromatic hydrocarbons such as
3-methylcholanthrene that induce the P-450Iisozyme(s), and
they correlate very closely to hepatic P-450I-dependent
LJ
I)
0
0
LJ
I
,
LUI
LUJ
D
D
C-)
12
10
8
6
4
2
0
9 I.,
0
E a
onD
0 0 C 0
C
I 0o
*. @~ ~ 3
: , - . I: I]-Il;.t.
I * II..
:... ..
:. :II
::II
179
t 'O
X 10, 0 0
E o.
VI X
c
a
.e m
3 0.c0
cLAMBERT ET AL.
activity (r = 0.9) (29,30). Caffeine clearance, the CBT, and
the CMR are induced in the human by smoking, and this
induction has been used as evidence that the three methods
are prianrily monitoring polyaromatic hydrocarbon-inducible
P4501 isozyme(s) (20,27,31). More recently, Campbell et al.
(32) used human hepatic microsomes in a reconstituted
microsomal system and demonstrated that caffeine
N-demethylation is blocked competitively by benzo(a)pyrene
and ethoxyresorufin, substrates that are metabolized by
P450I isozyme(s). There was also an excellent correlation
between caffeine N-demethylation activity and P-4501-
dependent ethoxyresorufin-O-deethylase activity in human
hepatic microsomes.
The two methods employed to monitor caffeine N-
demethylation were the CBT and CMR. The CBT monitors
caffeine 3-N-demethylase activity, the primary route ofcaf-
feine metabolism (20), by determiniing the rate ofexhalation
of labeled carbon dioxide derived from the nonradioactive
labeled [3-13C methyl] caffeine. The CMR monitors 7-N-
demethylation by comparing the molar ratio ofurinary caf-
feine metabolites that were demethylated at the 7-methyl
position to the metabolites thatwere not metabolized through
the 7-N-demethylation pathway (21). The identification of
which P-450I family isozyme is primarily responsible for 3-
and 7-N-demethylation of caffeine will have to await the
results ofin vitro caffeine metabolic studies using pure human
P-450I enzymes.
The PBB-exposed group's CBT and CMR values were
increased in comparison to the values ofthe urban subjects
not exposed to PBBs and were similar to the increased CBT
and CMR values of the adult smoker. This induction oc-
curred in exposed subjects with and without detectable HBB
levels. This suggests that ifthe PBBs were responsible for
some ofthe induction, the induction occurred at PBB body
burdens below detectable serum levels and/or there were
other chemicals in the rural environment that induced the
P-450I enzymes. It is ofnote that previous studies examiing
PCB and polychlorinated dibenzofuran levels and placental
P-450I activity reported the exposed groups had induced
P-450I levels but there was no correlation between the
chemical levels and P-450I activity (18).
The PBB exposure appears to at least partially induce
P-450I activity in the human as it does in the animal, since
there was a significant correlation between the increase in
PBB serum levels and the CBT. We did notidentify a corre-
lation between PBB level and CMR, and this may be due
to several reasons, including the fact that the subjects with
the highest CBT values did not complete the CMR.
There are many reasons why a close correlation between
PBB serum levels and P-4501 activity may not be present.
Genetically controlled factors of isozyme induction in the
human may prohibit the induction of all subjects exposed
to PBBs. These noninducible-subjects appear to make up
a considerable proportion ofthe population (20,27), thereby
notpermitting a close correlation. For example, ifonly one-
halfofthe subjects were genetically capable ofbeinginduced,
the maximal, r2 value would be very similar to the 0.2
value reported in this study.
Another factor that may affect the correlation between
PBB serumlevels and P-4501 activity is that the major PBB
congener, HBB, was measured in the serum and used as
the indicator for the PBB body burden. This congener in-
duces P-450II isozymes but not P-4501 isozymes in rodents
(1,2). Iffatbiopsies could have been performed, the fat level
of other congeners, particularly the congeners that are
potent inducers of the P-450I isozymes in animals, could
have been monitored, and the correlation between these
congeners and the caffeine tests may have been much closer.
The P-4501 activities in the PBB-exposed subjects were
lower in the female than the male subjects despite similar
PBB serum values. The cause(s) for this gender-related
difference is unknown, butoralcontraceptives that are known
(33) inhibitors of P-450 activity were excluded as a cause
ofthis gender-related effect, since only two ofthe females
reported they had taken oral contraceptives during the,
previous 2 months, and both had CBT values that were at
the median value. The males could have been exposed to
other chemicals capable of inducing the P-450I isozymes
or the females exposed to chemicals in the home that could
inhibit P-450I induction.
The apparent PBB-induced increase of the P-450I iso-
zyme(s) activity in the subjects was less than 55%. This
degree ofinduction was not as great as that seen in smokers
or in animals exposed to PBBs (2,19). This relatively small
induction may imply either the PBBs in FireMaster FF-1
were not potent inducers ofP-450I isozyme(s), and/or that
the human species is not very inducible by the PBBs. If
the induction ofP450I isozyme(s) is an indication ofpotential
toxicity, as it is in some animal species, than the PBB expo-
sure in the human may result in little toxicity. The definitive
data regarding the ultimate biologic effect of the PBB can
only be answered decades or possibly generations from
today.
The CBT and CMR may be valuable tools in biochemical
epidemiology since both are safe, noninvasive, and can be
readily performed in the field in subjects of all ages (24).
A good correlation (r2 = 0.54, p = 0.001) was observed
between the CBT and CMR, and each test has its unique
advantage and disadvantages (28).
In conclusion, the objectives of the study have been
accomplished. The HBB serum half-life was estimated to
be approximately 12 years, the PBB-exposed Michiganrural
residents were found to have induced P-450I activity which
was atleast partially due to the PBB exposure, and the CBT
and CMR were found to be easily conducted in the field
as monitors ofthe P-450I biomarker. Other studies will be
necessary to determine the polyhalogenated congeners that
are P-450I family inducers and to further explore the
significance, capacity, sensitivity, and specificity ofthe P-4501
biomarkers in human environmental toxicology studies.
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